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ABSTRACT
Objective To estimate whether migraine in mid-life is
associated with mortality from cardiovascular disease,
other causes, and all causes.
Design Population based cohort study.
Setting Reykjavik, Iceland.
Participants 18725 men and women, born 1907-35 and
living in Reykjavik and adjacent communities.
Main outcome measuresMortality from cardiovascular
disease, non-cardiovascular disease, and all causes.
Questionnaires and clinical measures were obtained in
mid-life (mean age 53, range 33-81) in the Reykjavik
Study (1967-91). Headache was classified as migraine
without aura, migraine with aura, or non-migraine
headache. Median follow-up was 25.9 years (0.1-40.
2 years), with 470990 person years and 10358 deaths:
4323 from cardiovascular disease and 6035 from other
causes. We used Cox regression to estimate risk of death
in those with migraine compared with others, after
adjusting for baseline risk factors.
Results People with migraine with aura were at increased
risk of all cause mortality (adjusted (for sex and
multivariables) hazard ratio 1.21, 95% confidence
interval 1.12 to 1.30) and mortality from cardiovascular
disease (1.27, 1.13 to 1.43) compared with people with
no headache, while those with migraine without aura and
non-migraine headache were not. Further examination of
mortality from cardiovascular disease shows that people
withmigraine with aura were at increased risk of mortality
from coronary heart disease (1.28, 1.11 to 1.49) and
stroke (1.40, 1.10 to 1.78). Women with migraine with
aura were also at increased risk of mortality from non-
cardiovascular disease (1.19, 1.06 to 1.35).
ConclusionsMigraine with aura is an independent risk
factor for cardiovascular and all cause mortality in men
and women. The risk of mortality from coronary heart
disease and stroke mortality is modestly increased in
people with migraine, particularly those with aura.
INTRODUCTION
In recent years, numerous studies have suggested that
migraine, particularly migraine with aura, is a risk fac-
tor for clinical and subclinical cardiovascular
disease.1-6 Both we and others have examined the
relation between cardiovascular risk factors and
migraine, showing differences in risk factors between
those with and without migraine.7-10 Less well under-
stood is the degree, if any, to which migraine is related
to the risk of all cause or cardiovascular mortality. Few
articles have been published on migraine and cardio-
vascular disease or overall mortality, with somewhat
conflicting findings, depictingmigraine as a risk factor,
neutral, or a protective factor.4 6 11-14 Because of insuffi-
cient data, a recent meta-analysis could draw no con-
clusions regarding the risk of mortality associated with
migrainewith aura.6We estimated the risk ofmortality
from cardiovascular disease, non-cardiovascular dis-
ease, and all causes associated with having migraine
with or without aura at mid-life during up to four dec-
ades of follow-up in a population based cohort.
METHODS
Study design
Detailed descriptions of the Reykjavik Study have pre-
viously been published.15 16 In brief, the Reykjavik
Study is a population based cohort study established
in 1967 by the Icelandic Heart Association to prospec-
tively study cardiovascular disease in Iceland.16 The
cohort included a random sample of men and women
born in 1907-35 and living in Reykjavik. The first
examination of each person occurred between 1967
and 1991, the average year of examination was 1975
(see appendix 1 on bmj.com).
Headache assessment
Participants were asked about current headache
symptoms.8 Those reporting headache once or more a
month were asked whether the headaches were accom-
panied by any of the following five features ofmigraine:
nausea or vomiting, unilateral location, photophobia,
visual disturbance during or preceding headache, and
unilateral numbness preceding headache.
We classified participants into four mutually exclu-
sive categories of headache: no headache once ormore
a month (reference category), non-migraine headache,
migraine without aura, and migraine with aura. The
category ofmigrainewithout aura included individuals
with headache with at least two of the three non-aura
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symptoms (nausea, unilateral location, photophobia).
The category ofmigrainewith aura included thosewho
reported visual aura or sensory aura, or both. Indivi-
duals with headache but no non-aura symptoms or
only one non-aura symptom were defined as having
non-migraine headache. Aura symptoms took prece-
dence over other symptoms. The classification scheme
represents an approximation of the 2004 diagnostic
criteria of the International Headache Society (IHS)17
for migraine with or without aura, which were forma-
lised after the Reykjavik Study data were collected.
Features for migraine without aura that are missing
from these IHS criteria include pulsatility, exacerba-
tion with activity, and phonophobia. Criteria for
migraine with aura missing from these criteria include
duration of aura (aura symptoms must last between 5
and 60 minutes) and speed of onset (aura symptoms
must develop gradually over more than 5 minutes).
Assessment of demographic and cardiovascular factors
Assessment of cardiovascular risk was performed at
the same time as the migraine assessment. Nurses
administered questionnaires, made physical measure-
ments, performed spirometry and electrocardiogra-
phy, and collected venous blood samples.
Endpoint definition
After entering the study, participantswere followed for
up to 40 years (until the end of 2007). Statistics relating
to the cause of death, given by an ICD (international
classification of disease) code, were obtained from Sta-
tistics Iceland. The main end points in our study were
deaths from cardiovascular disease, non-cardio-
vascular disease, and all causes. We also defined
three additional cardiovascular end points: fatal coron-
ary heart disease, fatal stroke, and other fatal cardio-
vascular disease (such as non-coronary heart disease
and non-stroke), based on diagnostic codes as defined
in the SCORE project (systematic coronary risk eva-
luation project).18 In the current study we split mortal-
ity from non-coronary atherosclerotic cardiovascular
disease (non-coronary heart disease-cardiovascular
disease) into mortality from stroke and other cardio-
vascular disease. An end point for fatal coronary
heart disease was obtained from hospital records,
which were systematically reviewed according to the
monitoring of trends and determinants in cardio-
vascular disease (MONICA) protocol.19
For stroke mortality we used ICD-9 (ninth revision)
codes 431, 433, 434, 436, and 438 and ICD-10 (10th
revision) codes I61, I63, I64, I66, and I69.
At the start of the study, there were 18903 partici-
pants, of whom 68 (0.36%) were lost to follow-up for
cause specific mortality and 110 (0.58%) had missing
data on blood pressure, cholesterol concentration, or
body mass index (BMI) and were omitted. This left a
sample of 18725 (99%), with 470 990 years of follow-
upduringwhich10358participantsdied. For cause spe-
cific mortality, 4323 died from cardiovascular disease
and 6035 from non-cardiovascular disease. The 4323
deaths from cardiovascular disease consisted of 2810
deaths from coronary heart disease, 927 from stroke,
and 586 from other forms of cardiovascular disease.
Statistical analysis
We used Cox proportional hazards to estimate the
relative risk of death (hazard ratio) after adjusting for
demographic and baseline risk factors for cardio-
vascular disease. Significance testing was two sided
and based on a 5% probability level. Risk factors for
mortality were entered into the Cox model in a step-
wise manner, including those with P values under 0.2
for multivariable adjustment. For all cause mortality,
we adjusted for age, BMI, education (primary, second-
ary, junior college, or university), smoking (none, cur-
rent, previous), and systolic and diastolic blood
pressure. For mortality from cardiovascular disease
we additionally adjusted for current diabetes mellitus,
cholesterol concentration, self reported history of cor-
onary event, self reported current use of anti-
hypertensive drugs, and use of oral contraceptives in
women.
We tested the Cox models for possible violations of
the proportional hazards assumption.2021 The assump-
tionwasnot violated except formenwithmigrainewith-
out aura when death from coronary heart disease was
the end point. When participants were censored after
30 years of follow-up, the proportional hazards assump-
tion held. This resulted in somewhat lower hazard ratio
for all three categories of headache compared with
when the follow-up was up to 40 years. We also used a
log−log plot. The curves for the groups in the current
study were roughly parallel, indicating no violation of
the proportionality of the hazards assumption.
We also estimated median life expectancy at age 50
by headache status from a Cox model adjusted for age.
Men and women were compared descriptively with
respect to headache/migraine status and mortality
from cardiovascular disease through Nelson-Aalen
cumulative hazard curves.2223 We estimated the abso-
lute 10 year risk ofmortality from all causes and cardio-
vascular disease by sex and headache status from the
Coxmodel at ages 50, 60, and 70. The software package
usedwasStata version9 (StataCorpLP,CollegeStation,
TX, USA) and SAS/STAT software version 9.2.
RESULTS
Table 1 shows the characteristics of the study partici-
pants. Therewere 9044men and 9681women, with an
average age of 52.8 (range 33-81) at study entry. Over-
all, 11% (2023) of the participants (6% (571) of men,
15% (1452) of women) were classified as having
migraine, including 3% with migraine without aura
(1% (128) of men, 5% (498) of women) and 8% with
migraine with aura (5% (443) of men, 10% (954) of
women). Among participants with aura, the propor-
tion with visual aura, sensory aura, and both visual
and sensory aura was 72%, 17%, and 11% for men
and 65%, 17%, and 19% for women, respectively.
Within the migraine with aura group, 81% (358) of
the men and 89% (849) of the women reported having
at least one other migraine symptom.
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Participantswithmigraine andheadachewere signif-
icantly younger than those without headache. Systolic
blood pressure was lower among men with migraine
than among men without headache (adjusted for age
and use of antihypertensive drugs). Pulse pressure
was lower among men and women with migraine
than those without headache and lower among men
with non-migraine headache than those without head-
ache (table 1). Compared with those without head-
ache, people with migraine or with migraine with
aura had less education and were more likely to be
taking antihypertensive drugs or hormone treatment,
or both.
Migraine and non-migraine headache
Compared with people with no headache, those with
migraine were at significantly increased risk of mortal-
ity from all causes (hazard ratio 1.15, 95% confidence
interval 1.08 to 1.23, P<0.001, table 2) and from
cardiovascular disease (1.22, 1.10 to 1.36, P<0.001,
table 3). The risk was similar with and without adjust-
ment for risk factors for cardiovascular disease. In
models stratified by sex, men and women with
migraine were at similarly increased risk of all cause
mortality (P=0.87 for interaction by sex), but for mor-
tality from cardiovascular diseasemenwere at margin-
ally higher risk than women (P=0.057 for interaction
by sex). Women, but not men, with non-migraine
headache were also at increased risk of mortality
from cardiovascular disease. The above results were
similar when we excluded the 266 people with a his-
toryof coronaryarterydisease fromthemodel.Table 4
shows results for mortality from non-cardiovascular
cause.
When we divided cardiovascular disease mortality
into deaths from coronary heart disease, stroke, or
other cardiovascular disease, people with migraine
were at increased risk of death from coronary heart
disease (sex and multivariable adjusted hazard ratio
1.22, 1.07 to 1.39, P=0.003, table 5) and stroke (1.30,
1.05 to 1.61, P=0.017, table 6). Risk of death from cor-
onary heart disease and stroke, however, was signifi-
cant only for men with migraine in the sex stratified
models. Men and women with migraine were not at
increased risk of mortality from other cardiovascular
diseases (table 7).
Table 1 | Characteristics of men and women at first examination according to migraine and headache status in Reykjavik Study (n=18 725*). Figures are
percentages of participants unless stated otherwise
Characteristic
Men Women
No
headache
Non-
migraine
headache† Migraine
Migraine
without
aura‡
Migraine
with aura§
No
headache
Non-
migraine
headache† Migraine
Migraine
without
aura‡
Migraine
with aura§
Mean (SD) age (years) 52.7 (8.6) 51.5 (8.7) 50.6 (8.2) 49.9 (7.3) 50.8 (8.4) 54.4 (9.0) 52.1 (9.0) 50.7 (8.4) 49.9 (8.1) 51.1 (8.6)
Mean (SD) BMI 25.8 (3.4) 25.9 (3.5) 25.6 (3.3) 25.6 (3.2) 25.6 (3.3) 25.2 (4.2) 25.1 (4.4) 24.8 (4.2) 24.7 (4.0) 24.9 (4.3)
Mean (SD) cholesterol
(mmol/l)
6.4 (1.1) 6.3 (1.0) 6.4 (1.1) 6.2 (1.1) 6.4 (1.1) 6.6 (1.3) 6.6 (1.2) 6.5 (1.2) 6.4 (1.2) 6.6 (1.2)
Mean (SD) systolic blood
pressure (mm Hg)
141.1 (21.1) 139.9 (21.6) 137.9 (20.6) 139.3 (22.5) 137.5 (20.1) 136.8 (22.5) 135.7 (21.8) 133.7 (20.7) 132.3 (19.4) 134.5 (21.3)
Mean (SD) diastolic blood
pressure (mm Hg)
89.3 (11.2) 90.2 (12.3) 88.8 (11.4) 90.6 (12.4) 88.3 (11.1) 84.1 (11.3) 84.3 (11.3) 84.1 (11.4) 83.3 (11.1) 84.5 (11.5)
Pulse pressure (mm Hg) 51.9 (15.0) 49.8 (14.2) 49.1 (13.8) 48.8 (13.8) 49.2 (13.8) 52.7 (16.1) 51.5 (15.5) 49.7 (14.5) 49.0 (13.1) 50.0 (15.2)
No of participants 7068 1405 571 128 443 6003 2226 1452 498 954
Headache NA 100 100 100 100 NA 100 100 100 100
Pain, unilateral NA 30 58 81 51 NA 27 67 80 60
Nausea/vomiting NA 4 37 66 28 NA 9 62 80 53
Photophobia NA 7 46 68 40 NA 7 59 65 56
Visual symptoms NA NA 64 NA 82 NA NA 55 NA 84
Sensory symptoms NA NA 22 NA 28 NA NA 23 NA 35
Elementary or less
education
33 36 38 33 39 55 54 55 50 57
Hypertension treatment 7 8 8 9 8 11 12 10 8 11
Current smoking 55 56 56 52 58 41 40 40 36 42
Former smoking 23 24 24 25 23 15 15 16 18 16
Medical hormone use 0.3 0.4 1 1 1 5 7 9 8 9
Oral contraceptive use NA NA NA NA NA 3 5 6 6 5
Diabetes 4 5 4 6 4 3 3 3 2 4
History of coronary event¶ 3 2 1 0 1 1 0.4 0.4 0.4 0.4
NA=not applicable.
*Of original 18 903 participants, 68 (0.36%) were lost to follow-up and 110 (0.58%) had missing data on blood pressure, cholesterol concentration, or BMI.
†Headache without or with one symptom of migraine once or more a month.
‡2-3 of unilateral, photophobia, nausea symptoms.
§Migraine with visual or sensory symptoms, or both. Participants with symptoms of migraine without aura and migraine with aura were classified as migraine with aura.
¶Myocardial infarction, angioplasty, or coronary artery bypass graft.
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Migraine with aura and without aura
Among people with migraine, those with migraine
with aura were at increased risk of mortality from all
causes and cardiovascular disease (tables 2 and 3), but
no increased risk was seen in those withmigraine with-
out aura. We studied the long term effects of migraine
on mortality from cardiovascular disease using cumu-
lative hazard curves. Men with migraine with aura
were at marginally higher risk than women with
migraine with aura (figure); this is also reflected in
table 3, but this difference was marginally significant
(P=0.053 for interaction by sex). Women with
migrainewith aurawere still atmarginally significantly
increased risk of cardiovascular diseasemortality com-
pared with women with no headache (1.18, 1.00 to
1.40, P=0.053, table 3).
The increased risk of mortality from cardiovascular
disease in people with migraine with aura was higher
among men than women for coronary heart disease
and stroke, although not significantly; hazard ratios
were 1.43 in men versus 1.17 in women for mortality
from coronary heart disease (table 5) and 1.76 in men
versus1.26 inwomenformortality fromstroke (table 6)
(P=0.12 and 0.15 for interaction by sex for coronary
heart disease and stroke mortality). To investigate this
finding further, we divided non-cardiovascular disease
Table 2 | Age and multivariable* adjusted hazard ratios (95% confidence intervals) for mortality from all cause according to
migraine status in men and women in Reykjavik Study (n=18 725†)
No headache Non-migraine headache‡ Migraine Migraine without aura§ Migraine with aura¶
Men
Died/total 4519/7068 845/1405 364/571 73/128 291/443
Age adjusted 1.00 0.99 (0.92 to 1.07) 1.12 (1.01 to 1.25)** 0.92 (0.73 to 1.17) 1.19 (1.05 to 1.36)**
Multivariable adjusted 1.00 0.99 (0.92 to 1.06) 1.16 (1.04 to 1.29)** 0.95 (0.76 to 1.20) 1.23 (1.09 to 1.38)**
Women
Died/total 2958/6003 1008/2226 664/1452 198/498 466/954
Age adjusted 1.00 1.02 (0.95 to 1.10) 1.12 (1.03 to 1.22)** 1.00 (0.86 to 1.15) 1.18 (1.07 to 1.31)**
Multivariable adjusted 1.00 1.04 (0.97 to 1.12) 1.16 (1.07 to 1.26)** 1.06 (0.92 to 1.22) 1.21 (1.09 to 1.33)**
Men and women
Died/total 7477/13 071 1853/3631 1028/2023 271/626 757/1397
Age-sex adjusted 1.00 1.01 (0.96 to 1.06) 1.12 (1.05 to 1.19)** 0.97 (0.86 to 1.09) 1.18 (1.10 to 1.27)**
Multivariable adjusted 1.00 1.01 (0.96 to 1.07) 1.15 (1.08 to 1.23)** 1.02 (0.91 to 1.16) 1.21 (1.12 to 1.30)**
*Age, BMI, smoking (no, current, previous), education (primary, secondary, college/university), systolic and diastolic blood pressure, and use of
antihypertensive drugs.
†Of original 18 903 participants, 68 (0.36%) were lost to follow-up and 110 (0.58%) had missing data on blood pressure, cholesterol concentration,
or BMI, leaving n=18 725 with 470 990 years of follow-up.
‡Headache without or with one symptom of migraine once or more a month.
§2-3 of unilateral, photophobia, nausea symptoms.
¶Migraine with visual or sensory symptoms, or both. Participants with symptoms of migraine without aura and migraine with aura were classified as
migraine with aura.
**Significant at P<0.05.
Table 3 | Age and multivariable* adjusted hazard ratios (95% confidence intervals) for mortality from cardiovascular disease
according to migraine status in men and women in Reykjavik Study (n=18 725†)
No headache Non-migraine headache‡ Migraine Migraine without aura§ Migraine with aura¶
Men
Died/total 2086/7068 388/1405 189/571 38/128 151/443
Age adjusted 1.00 0.99 (0.89 to 1.10) 1.28 (1.11 to 1.49)** 1.07 (0.78 to 1.48) 1.35 (1.15 to 1.60)**
Multivariable adjusted 1.00 0.97 (0.87 to 1.08) 1.35 (1.17 to 1.57)** 1.14 (0.83 to 1.57) 1.42 (1.20 to 1.68)**
Women
Died/total 1061/6003 377/2226 222/1452 66/498 156/954
Age adjusted 1.00 1.12 (1.00 to 1.26) 1.15 (0.99 to 1.33) 1.04 (0.81 to 1.34) 1.20 (1.01 to 1.42)**
Multivariable adjusted 1.00 1.13 (1.01 to 1.27)** 1.16 (1.00 to 1.34) 1.09 (0.85 to 1.40) 1.18 (1.00 to 1.40)
Men and women
Died/total 3147/13 071 765/3631 411/2023 104/626 307/1397
Age-sex adjusted 1.00 1.04 (0.96 to 1.13) 1.19 (1.07 to 1.32)** 1.02 (0.84 to 1.24) 1.25 (1.11 to 1.41)**
Multivariable adjusted 1.00 1.04 (0.96 to 1.13) 1.22 (1.10 to 1.36)** 1.10 (0.91 to 1.34) 1.27 (1.13 to 1.43)**
*Age, BMI, smoking (no, current, previous), education (primary, secondary, college/university), systolic and diastolic blood pressure, use of
antihypertensive drugs, cholesterol concentration, diabetes, history of coronary artery disease, and birth control use for women.
†Of original 18 903 participants, 68 (0.36%) were lost to follow-up and 110 (0.58%) had missing data on blood pressure, cholesterol concentration,
or BMI, leaving n=18 725 with 470 990 years of follow-up.
‡Headache without or with one symptom of migraine once or more a month.
§2-3 of unilateral, photophobia, nausea symptoms.
¶Migraine with visual or sensory symptoms, or both. Participants with symptoms of migraine without aura and migraine with aura were classified as
migraine with aura.
**Significant at P<0.05.
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into cancer and non-cancer and found that the risk was
increased only for mortality other than cancer 1.33,
1.13 to 1.57, P=0.001) (see appendix 2 on bmj.com).
Overall, using total mortality, our model suggests
that at age 50 men and women with migraine with
aura had a median loss of 1.5 and 1.4 years of life,
respectively, compared with those without headache
(see appendix 3 on bmj.com).
At age 50 the absolute risk of all cause mortality was
low but still considerably higher for men than for
women. For example, the 10 year risk for men aged
50 was 6.8% in those with no headache and 8.0% in
those with migraine with aura; the corresponding
values for women were 3.0% and 3.6%. At age 70 the
absolute 10 year risk had risen to 40.6% and 46.1% for
men and 24.1% and 27.9% for women (see appendix 4
on bmj.com).
DISCUSSION
Principal findings
In this cohort studywithover 470 000personyears and
a median follow-up of 26 years, men and women with
migraine with aura were shown to be at increased risk
ofmortality fromall causes and cardiovascular disease,
Table 4 | Age and multivariable* adjusted hazard ratios (95% confidence intervals) for mortality from non-cardiovascular
disease (mortality from causes other than cardiovascular disease) according to migraine status in men and women in
Reykjavik Study (n=18 725†)
No headache Non-migraine headache‡ Migraine Migraine without aura§ Migraine with aura¶
Men
Died/total 2433/7068 457/1405 175/571 35/128 140/443
Age adjusted 1.00 0.99 (0.90 to 1.09) 0.99 (0.85 to 1.15) 0.81 (0.58 to 1.13) 1.05 (0.88 to 1.24)
Multivariable adjusted 1.00 0.98 (0.89 to 1.09) 1.00 (0.86 to 1.17) 0.83 (0.59 to 1.16) 1.05 (0.89 to 1.25)
Women
Died/total 1897/6003 631/2226 442/1452 132/498 310/954
Age adjusted 1.00 0.97 (0.88 to 1.06) 1.11 (1.00 to 1.23) 0.97 (0.81 to 1.16) 1.17 (1.04 to 1.32)**
Multivariable adjusted 1.00 0.99 (0.90 to 1.08) 1.14 (1.02 to 1.26)** 1.02 (0.86 to 1.22) 1.19 (1.06 to 1.35)**
Men and women
Died/total 4330/13 071 1088/3631 617/2023 167/626 450/1397
Age-sex adjusted 1.00 0.98 (0.91 to 1.05) 1.07 (0.98 to 1.17) 0.93 (0.80 to 1.09) 1.13 (1.03 to 1.25)**
Multivariable adjusted 1.00 0.99 (0.92 to 1.05) 1.10 (1.01 to 1.19)** 0.97 (0.83 to 1.14) 1.15 (1.04 to 1.27)**
*Age, BMI, smoking (no, current, previous), education (primary, secondary, college/university), systolic and diastolic blood pressure, and use of
antihypertensive drugs.
†Of original 18 903 participants, 68 (0.36%) were lost to follow-up and 110 (0.58%) had missing data on blood pressure, cholesterol concentration,
or BMI, leaving n=18 725 with 470 990 years of follow-up.
‡Headache without or with one symptom of migraine once or more a month.
§2-3 of unilateral, photophobia, nausea symptoms.
¶Migraine with visual or sensory symptoms, or both. Participants with symptoms of migraine without aura and migraine with aura were classified as
migraine with aura.
**Significant at P<0.05.
Table 5 | Risk of mortality from coronary heart disease according to migraine status in men and women in Reykjavik Study
(n=18 725*). Figures are age and multivariable† adjusted hazard ratios (95% confidence intervals)
No headache Non-migraine headache‡ Migraine Migraine without aura§ Migraine with aura¶
Men
Died/total 1473/7068 275/1405 136/571 26/128 110/443
Age adjusted 1.00 0.99 (0.87 to 1.12) 1.29 (1.08 to 1.54)** 1.03 (0.70 to 1.52) 1.38 (1.13 to 1.67)**
Multivariable adjusted 1.00 0.96 (0.85 to 1.10) 1.36 (1.14 to 1.62)** 1.12 (0.76 to 1.65) 1.43 (1.18 to 1.74)**
Women
Died/total 590/6003 213/2226 123/1452 35/498 88/954
Age adjusted 1.00 1.13 (0.96 to 1.32) 1.13 (0.93 to 1.37) 0.98 (0.69 to 1.38) 1.20 (0.96 to 1.51)
Multivariable adjusted 1.00 1.14 (0.98 to 1.34) 1.13 (0.93 to 1.37) 1.03 (0.73 to 1.46) 1.17 (0.93 to 1.47)
Men and women
Died/total 2063/13 071 488/3631 259/2023 61/626 198/1397
Age-sex adjusted 1.00 1.04 (0.94 to 1.14) 1.19 (1.04 to 1.35)** 0.97 (0.75 to 1.25) 1.28 (1.10 to 1.48)**
Multivariable adjusted 1.00 1.03 (0.94 to 1.14) 1.22 (1.07 to 1.39)** 1.05 (0.82 to 1.37) 1.28 (1.11 to 1.49)**
*Of original 18 903 participants, 68 (0.36%) were lost to follow-up and 110 (0.58%) had missing data on blood pressure, cholesterol concentration,
or BMI, leaving n=18 725 with 470 990 years of follow-up.
†Age, BMI, smoking (no, current, previous), education (primary, secondary, college/university), systolic and diastolic blood pressure, and use of
antihypertensive drugs.
‡Headache without or with one symptom of migraine once or more a month.
§2-3 of unilateral, photophobia, nausea symptoms.
¶Migraine with visual or sensory symptoms, or both. Participants with symptoms of migraine without aura and migraine with aura were classified as
migraine with aura.
**Significant at P<0.05.
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while those with migraine without aura were not at
increased risk. Risk of mortality from cardiovascular
disease was marginally more increased in men than
in women with migraine and aura. Migraine with
aura is an independent risk factor for cardiovascular
and all cause mortality in men and women but weaker
than major established risk factors, such as cigarette
smoking, diabetes, and high blood pressure.
Strengths and limitations
This study had a large cohort, with a broad age range,
long follow-up, and comprehensive data on
conventional risk factors for cardiovascular disease at
baseline as well as high ascertainment (>99%) of cause
specific mortality. The cohort is population based,
which adds to the generalisability of our results.
Although our classification of migraine precedes the
2004 IHS criteria, the questions are similar to those cur-
rently asked in the IHS criteria and cover themost com-
mon symptoms of migraine.
We did not ask about symptoms ofmigraine in those
who reported having headache less than once a month
and so are therefore likely to capture only those with
higher attack frequency. People who had migraine
Table 6 | Risk of mortality from stroke* according to migraine status in men and women in Reykjavik Study (n=18 725†).
Figures are age and multivariable‡ adjusted hazard ratios (95% confidence intervals)
No headache Non-migraine headache§ Migraine Migraine without aura¶ Migraine with aura**
Men
Died/total 373/7068 63/1405 37/571 6/128 31/443
Age adjusted 1.00 0.92 (0.70 to 1.20) 1.46 (1.04 to 2.05)†† 0.97 (0.43 to 2.18) 1.62 (1.12 to 2.34)††
Multivariable adjusted 1.00 0.90 (0.69 to 1.18) 1.55 (1.10 to 2.18)†† 0.96 (0.43 to 2.15) 1.76 (1.22 to 2.54)††
Women
Died/total 292/6003 99/2226 63/1452 18/498 45/954
Age adjusted 1.00 1.08 (0.86 to 1.36) 1.20 (0.91 to 1.58) 1.05 (0.65 to 1.69) 1.27 (0.92 to 1.74)
Multivariable adjusted 1.00 1.08 (0.86 to 1.36) 1.20 (0.91 to 1.59) 1.08 (0.67 to 1.75) 1.26 (0.92 to 1.73)
Men and women
Died/total 665/13 071 162/3631 100/2023 24/626 76/1397
Age-sex adjusted 1.00 1.01 (0.85 to 1.20) 1.27 (1.03 to 1.58)†† 1.01 (0.67 to 1.53) 1.38 (1.09 to 1.76)††
Multivariable adjusted 1.00 1.00 (0.84 to 1.19) 1.30 (1.05 to 1.61)†† 1.06 (0.70 to 1.60) 1.40 (1.10 to 1.78)††
*ICD-9 codes 431, 433, 434, 436, 438 and ICD-10 codes I61, I63, I64, I66, and I69.
†Of original 18 903 participants, 68 (0.36%) were lost to follow-up and 110 (0.58%) had missing data on blood pressure, cholesterol concentration,
or BMI, leaving n=18 725 with 470 990 years of follow-up.
‡Age, BMI, smoking (no, current, previous), education (primary, secondary, college/university), systolic and diastolic blood pressure, and use of
antihypertensive drugs.
§Headache without or with one symptom of migraine once or more a month.
¶2-3 of unilateral, photophobia, nausea symptoms.
**Migraine with visual or sensory symptoms, or both. Participants with symptoms of migraine without aura and migraine with aura were classified as
migraine with aura.
††Significant at P<0.05.
Table 7 | Risk of mortality from cardiovascular disease other than coronary heart disease and stroke according to migraine
status in men and women in Reykjavik Study (n=18 725*). Figures are age and multivariable† adjusted hazard ratios (95%
confidence intervals)
No headache Non-migraine headache† Migraine Migraine without aura‡ Migraine with aura§
Men
Died/total 240/7068 50/1405 16/571 6/128 10/443
Age adjusted 1.00 1.14 (0.84 to 1.54) 0.97 (0.58 to 1.60) 1.46 (0.65 to 3.29) 0.80 (0.43 to 1.51)
Multivariable adjusted 1.00 1.12 (0.83 to 1.53) 1.04 (0.63 to 1.73) 1.54 (0.68 to 3.47) 0.87 (0.46 to 1.64)
Women
Died/total 179/6003 65/2226 36/1452 13/498 23/954
Age adjusted 1.00 1.19 (0.89 to 1.58) 1.16 (0.81 to 1.67) 1.29 (0.73 to 2.28) 1.10 (0.71 to 1.71)
Multivariable adjusted 1.00 1.21 (0.91 to 1.61) 1.20 (0.83 to 1.72) 1.33 (0.75 to 2.35) 1.13 (0.73 to 1.76)
Men and women
Died/total 419/13 071 115/3631 52/2023 19/626 33/1397
Age sex adjusted 1.00 1.15 (0.93 to 1.42) 1.06 (0.79 to 1.42) 1.29 (0.81 to 2.05) 0.97 (0.68 to 1.38)
Multivariable adjusted 1.00 1.15 (0.93 to 1.42) 1.12 (0.83 to 1.50) 1.39 (0.87 to 2.21) 1.00 (0.70 to 1.43)
*Of original 18 903 participants, 68 (0.36%) were lost to follow-up and 110 (0.58%) had missing data on blood pressure, cholesterol concentration,
or BMI., leaving n=18 725 with 470 990 years of follow-up.
†Age, BMI, smoking (no, current, previous), education (primary, secondary, college/university), systolic and diastolic blood pressure, and use of
antihypertensive drugs.
‡Headache without or with one symptom of migraine once or more a month.
§2-3 of unilateral, photophobia, nausea symptoms.
¶Migraine with visual or sensory symptoms, or both. Participants with symptoms of migraine without aura and migraine with aura were classified as
migraine with aura.
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aura exclusively, without headache,would be included
in the “no headache” group because of our screening
question. We cannot draw any conclusions from the
current study about the risk of mortality for people
with migraine with low frequency of attacks (less than
once a month) and those with migraine aura without
headache.
The risk of cardiovascular outcomesmight be higher
in people with more frequent attacks of migraine.
Kurth et al looked at frequency of attacks and risk of
cardiovascular disease in a cohort of US women.24
They reported a J-shaped association between attack
frequency and risk. If this J-shaped association applies
to our current study, our estimates might be somewhat
lower than we would have found if we had included
everyone with migraine, although this is speculative.
The prevalence of aura (as a proportion of the total
migraine population) is higher than has been reported
in other population studies and might include com-
monly occurring non-specific visual symptoms such
as blurring. The result of this misclassification would
probably attenuate the relation betweenmigraine with
aura and mortality. We note that our prevalence of
migraine overall (with and without aura combined),
however, is highly consistent with previous studies.25
Finally, the combination of visual symptoms and
headache can be symptoms of a transient ischaemic
attack. If this were misclassified as migraine with aura
in our study, it might exaggerate the association
between migraine and mortality from cardiovascular
disease. Our diagnosis of migraine, however, required
headache at least once a month in the past 12 months,
which is not a feature of transient ischaemic attack.
Therefore we believe it is unlikely that this type of mis-
classification would have appreciably affected our
results.
As we have data on vascular risk factors only at base-
line, we did not adjust for potential changes in such risk
factors that might have developed after the start of the
study. These risk factors in adults tend to track over
time26—that is, those at high risk tend to stay at high
risk during follow-up and those at low risk tend to
stay at low risk. While residual confounding because
of imperfect control for vascular risk factors at baseline
or after the start of the study is a possibility,wenote that
the hazard ratios scarcely changed after adjustment,
arguing against a strong role for this sort of error.
Although about only 2%of affected people have new
onsetmigraine over the age of 50,27 the younger people
in the cohort might have developed migraine after the
study started and not been counted. We suggest that
such a low percentage of people with migraine would
be unlikely to change the risk estimates in the current
study. Neither data on migraine specific treatment,
such as ergotamine and triptans, nor data on the use
of analgesics or steroid treatment were available. We
could not therefore estimate the potential modifying
effects of these drugs on the association between
migraine and cardiovascular disease.
Comparison with other studies
This population based cohort study measured mortal-
ity from all causes and cardiovascular disease in men
and women with migraine separately by aura status.
Our findings are consistent with the increasing evi-
dence that migraine, particularly migraine with aura,
is associatedwith cardiovascular disease.1 3 4 28 Previous
reports in which migraine has been shown to be pro-
tective for all cause mortality11 12 14 could be explained
by methodological differences with this study. For
example, two of these studies12 14 were based on patient
based rather than population based samples. Further-
more, one of these studies14 identified those with
migraine based in part on their use of triptans, which
are contraindicated in people with risk factors for
cardiovascular disease. The aim of the two studies12 14
was not to compare risk in those with and without
migraine but to assess possible risk of triptans in people
withmigraine. The fact that those two studies showed a
protective effect could also explain why a recent meta-
analysis of five studies (including those two studies)
showed no risk for mortality from cardiovascular dis-
ease associatedwithmigraineoverall (with andwithout
aura combined) (relative risk 1.03, 0.79 to 1.34).6 Only
one study included in that meta-analysis estimated the
risk of mortality separately in people with migraine
with aura.4 This study suggested that women with
migraine with aura were at about twice the risk of
cardiovascular mortality compared with women with-
out headache.
The hazard ratios for mortality for cardiovascular
disease in men with migraine were somewhat higher
than the corresponding values for all cause mortality.
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The risk was independent of traditional risk factors for
cardiovascular disease measured at baseline. Several
studies have reported greater risk of stroke in people
with migraine16 28 than in others, especially for those
with aura.1 4 6 28 The risk of coronary heart disease
among people with migraine varies more between stu-
dies, from being lower than normal to being moder-
ately increased.6 In our study the risk increase for
mortality from coronary heart disease wasmainly con-
fined to men with migraine with aura.
The increased risk of overall mortality or mortality
related to cardiovascular disease associated with
migraine with aura is significant but modest: 20% for
women and 20% formen,with respect to all causemor-
tality, and 18% for women and 42% for men, with
respect to cardiovascular disease mortality.
We estimated that at age 50 men and women with
migrainewith aura had amedian loss of 1.5 or 1.4 years
of life compared with those without headache. By way
of comparisonwithmore established risk factors for all
causemortality, themedian loss of life in theReykjavik
Study for those with untreated high blood pressure
(≥160 mmHg), type 2 diabetes, and smoking 15 cigar-
ettes or more a day was, respectively, about 5, 5, and
13 years for men and 3, 3, and 9 years for women2930
(see appendix 3 on bmj.com).
In people with migraine with aura, compared with
those without headache, the excess absolute 10 year
risk of all cause mortality at age 50 was low: 1.2% for
men (8.0% v 6.8% risk of all cause mortality) and 0.6%
for women (3.6% v 3.0%). At age 70, the excess abso-
lute risk of all cause mortality in people with migraine
with aura was higher, at 5.5% for men (46.1% v 40.6%)
and 3.8% for women (27.9% v 24.1%).
Potential mechanisms
Several mechanisms could explain the link between
migraine and cardiovascular disease, though none
has been definitively established.Migraine and ischae-
mic events have been linked through a genetic
component.31 They might reflect associations between
migraine with aura and vasculopathy32 and mitochon-
drial myopathy, encephalopathy, lactic acidosis, and
stroke (MELAS).33 Methylenetetrahydrofolate reduc-
tase (MTHFR) is an important enzyme in the meta-
bolism of homocysteine, derived from the amino acid
methionine, and a risk factor for cerebral small vessel
disease34 andmigraine.35Migraine coulddirectly cause
an ischaemic event that is from a migrainous infarct,
but such events are rare, about 3% of all strokes,36
and can therefore account for only a small proportion
of all strokes in people with migraine. There is increas-
ing evidence that migraine is associated with coronary
heart disease,4 37 and one study reported an association
betweenmigraine and an increased prevalence of con-
ventional vascular risk factors.9 The current data show
little difference in risk factors between those with and
withoutmigraine, which is in linewith previous studies
on peoplewithmigraine in theReykjavik Study.7 8Our
results were similar with and without adjustment for
conventional risk factors for cardiovascular disease,
suggesting that the mechanism(s) linking migraine to
cardiovascular disease are from a different pathway.
Others have reported that people with migraine, even
in the absence of conventional risk factors, are at
increased risk of stroke37 and have decreased cerebral
and peripheral vascular resistance, retinal microvascu-
lar signs, hypercoagulability, and inflammation,31 38
supporting the hypothesis thatmigrainemight be a sys-
temic disorder that is affecting vasculature.39 People
with migraine have been shown to have altered vascu-
lar reactivity at a young age (under 25 years),40 which
indicates that there might be a factor affecting both the
onset of migraine and progression of cardiovascular
disease early in life. A recent study reported that peo-
ple with migraine without aura had reduced function
and number of endothelial progenitor cells,38 which
has been associated with higher Framingham risk
scores in people with coronary heart disease41 and
increased risk of mortality from cardiovascular
disease.42
Implications
People withmigraine, particularly those withmigraine
with aura, are at amodestly increased risk of mortality,
independent of classic risk factors for cardiovascular
disease measured in mid-life. The absolute risk is low,
and the focus should be on conventional risk factors,
such as hypertension, smoking, and adverse lipid pro-
file, for reducing the risk of cardiovascular disease,
regardless of migraine status.
Future research
More research is needed on the association between
migraine and mortality from cardiovascular disease,
non-cardiovascular disease, and all causes, including
studies to identify whether there are specific subgroups
of people with migraine who are at particular risk
because of genetic or environmental factors. Future
studies should assess aura status and frequency of
attacks in detail, and prospective studies can monitor
changes in the risk profile for cardiovascular disease
WHAT IS ALREADY KNOWN ON THE TOPIC
Individuals with migraine with aura (but not without aura) are at almost twice the risk of
ischaemic stroke than other people
Individuals withmigraine (with and without aura combined) are not at increased risk of death
from cardiovascular disease
Compared with women without headache, women with migraine with aura (but not without
aura) are at increased risk of death from cardiovascular disease after age 45
WHAT THIS STUDY ADDS
Migraine with aura is an independent risk factor for cardiovascular and all cause mortality in
both men and women but is weaker than major established risk factors, such as smoking,
diabetes, and high blood pressure
Women with migraine with aura were at increased risk of mortality from non-cardiovascular
disease
People with migraine, particularly those with aura, were at increased risk of death from
coronary heart disease and stroke
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over time to better understand the aetiology andpatho-
physiologyofmigraine in its development. Finally, stu-
dies are needed to determine if reducing the frequency
of attacks with migraine preventive treatment might
reduce the risk of cardiovascular disease.
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